Development of the Mainz Resilience Assessment for Pediatric Cancer: A New Age-Specific Patient-Reported Outcome Tool to Evaluate Resilience in Young Cancer Patients - Top-Institutions - MDSpire

Development of the Mainz Resilience Assessment for Pediatric Cancer: A New Age-Specific Patient-Reported Outcome Tool to Evaluate Resilience in Young Cancer Patients

  • By

  • Marie A. Neu

  • Franziska Ortmüller

  • Abigale L. Robinson

  • Elias Dreismickenbecker

  • Henrike Otto

  • Lena Wypyrsczyk

  • Mareike Kühn

  • Michèle Wessa

  • Oliver Tüscher

  • Joerg Faber

  • February 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Oncology
    • Psychosocial Oncology
    • Patient-Reported Outcomes

  • #2

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center
    Dana-Farber/Boston Children's Cancer and Blood Disorders Center

    Boston, MA

    Key Differentiators

    • Pediatric Oncology
    • Psychology
    • Behavioral Medicine

  • #3

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Oncology
    • Psychosocial Research
    • Clinical Psychology

  • #4

    University of California, San Francisco (UCSF) Benioff Children's Hospital
    University of California, San Francisco (UCSF) Benioff Children's Hospital

    San Francisco, CA

    Key Differentiators

    • Pediatric Oncology
    • Psychosocial Oncology
    • Health Outcomes Research

  • #5

    Memorial Sloan Kettering Cancer Center (MSKCC) Pediatric Oncology
    Memorial Sloan Kettering Cancer Center (MSKCC) Pediatric Oncology

    New York, NY

    Key Differentiators

    • Pediatric Oncology
    • Psychosocial Oncology
    • Patient-Reported Outcomes

Original Source(s)

Development of the Mainz Resilience Assessment for Pediatric Cancer: A New Age-Specific Patient-Reported Outcome Tool to Evaluate Resilience in Young Cancer Patients

  • by Marie A. Neu, Franziska Ortmüller, Abigale L. Robinson, Elias Dreismickenbecker, Henrike Otto, Lena Wypyrsczyk, Mareike Kühn, Michèle Wessa, Oliver Tüscher, Joerg Faber

  • February 26, 2026

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities